RxDoctor Payments Data

Vidyasaga Anmangandla, MD

Internal Medicine · White Plains, MDNPI 1073589206

Payments from drug & device makers

$653in general payments, 2019–2025

Across 13 payments — averaging $50.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$148
  • Novo Nordisk$125
  • E.r. Squibb & Sons, L.L.C.$90
  • Novartis$76
  • GSK$72
  • Johnson & Johnson$63
  • plus $79 from 5 others

What the payments were for

  • Food & beverage$64198%
  • Education$122%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$653 in reported general payments places this provider in the 65th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$452,467
Medicare patients
372
Services billed
11,151

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide47$81,123
EliquisApixaban59$71,993
XareltoRivaroxaban31$33,814
TrulicityDulaglutide20$22,694
FarxigaDapagliflozin Propanediol24$22,332
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$22,275
JardianceEmpagliflozin20$17,137
JanuviaSitagliptin Phosphate12$13,419
MyrbetriqMirabegron11$13,092
Ezetimibe302$11,669
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$11,173
Aimovig AutoinjectorErenumab-Aooe11$8,740
Rosuvastatin Calcium348$6,158
DapagliflozinDapagliflozin Propanediol11$5,076
EdarbiAzilsartan Medoxomil14$5,056

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus$125$81,12347 claims
PfizerEliquis$11$71,99359 claims
Johnson & JohnsonXarelto$63$33,81431 claims
GSKTrelegy Ellipta, Anoro Ellipta$72$33,44832 claims
Lilly USA, LLCTrulicity$12$22,69420 claims
AstraZenecaFarxiga$18$22,33224 claims
Astellas Pharma US IncMyrbetriq$19$13,09211 claims
AbbVieSynthroid$19$1,68535 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in White Plains

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →